Molecular Partners (MOLN) said late Wednesday that updated data from a phase 1/2a study of MP0533 showed three out of eight patients with relapsed or refractory acute myeloid leukemia responded after the first cycle of a steeper step-up dosing in group eight.
One patient in the group achieved a complete response, while the remaining two patients had a complete response with partial hematologic recovery, the company said.
The company said it is dosing patients in group nine and expects data from the amended dosing scheme in H2.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。